Check­Mate-451: Bris­tol-My­ers’ Op­di­vo — plus Yer­voy — fails PhI­II com­bo lung can­cer study, the lat­est in a se­ries of set­backs

Bris­tol-My­ers Squibb $BMY is be­com­ing well prac­ticed at dis­ap­point­ing in­vestors with their R&D strat­e­gy for lung can­cer.

Af­ter the mar­ket closed Mon­day the phar­ma gi­ant …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER